Nabih Naim

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 8

Top Topics

Vascular Endothelial Growth Factor

Small Cell Lung Cancer

Renal Cell Carcinoma

Top Venues

Future oncology (London, England)

Personalized medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Joseph Zouein, Nabih Naim, Hampig Raphael Kourie
Adjuvant therapy in renal cell carcinoma in the immunotherapy era: where do we stand? Immunotherapy 15 (2) (2023)
Joseph Zouein, Nabih Naim, Hampig Raphael Kourie
Adjuvant therapy in renal cell carcinoma in the immunotherapy era: where do we stand? Immunotherapy 15 (2) (2023)
Hampig Raphael Kourie, Mervat Mahrous, Nabih Naim, Joseph Zouein, Zineb Benbrahim, Kakil Rasul, Mohsen Mokhtar, Ahmad Al Shehri, Mahmoud Shakeeb, Sami Khatib, Humaid Al-Shamsi, Ali Shamseddine, Elisabeth Smyth
The first Middle East and North Africa expert consensus recommendations for management of advanced gastric cancer. Future oncology (London, England) (2023)
Sasha-Jane Abi-Aad, Joseph Zouein, Antoine Chartouni, Nabih Naim, Hampig Raphael Kourie
Simultaneous inhibition of PD-1 and LAG-3: the future of immunotherapy? Immunotherapy (2023)
Joseph Zouein, Nabih Naim, Hampig Raphael Kourie
Adjuvant therapy in renal cell carcinoma in the immunotherapy era: where do we stand? Immunotherapy 15 (2) (2023)
Joseph Zouein, Nabih Naim, Hampig Raphael Kourie
Adjuvant therapy in renal cell carcinoma in the immunotherapy era: where do we stand? Immunotherapy (2023)
Hampig Raphaël Kourie, Fahad Ibnshamsah, Joseph Zouein, Nabih Naim, Salah Abbasi, Nasr Allahloubi, Manwar Al-Naqqash, Ashwaq Alolayan, Ahmed Alshehri, Nizar Bitar, Adda Bounedjar, Abdulaziz Al Farsi, Humaid El Shamsi, Ramy Ghali, Hassan Jaafar, Blaha Larbaoui, Mervat Mahrous, Hind Mrabti, Abdul Razzak Nweir, Mohamed Oukkal, Kakil Rasul, Mohsen Razavi, Rim Turfa, Sami Khatib, Ali Shamseddine
The first Middle East and North Africa expert consensus recommendations for the management of advanced colorectal cancer. Future oncology (London, England) 18 (24) (2022)
Nabih Naim, Sara Moukheiber, Karim Jaber, Hampig Raphael Kourie
After decades, RAS mutation has finally become a therapeutic target. Personalized medicine 18 (6) (2021)